News

Yes Pharma to attend the DCAT in New York, USA. March 10 - 13, 2014

Yes Pharma to attend the DCAT in New York, USA. March 10 - 13, 2014. To schedule a meeting with our representative at the show , Click here >>

Read More

Yes Pharma to attend the SupplySide West in Las Vegas, USA. November 14-15, 2013

Yes Pharma to attend the SupplySide West in Las Vegas, USA. November 14-15, ...

Read More

Yes Pharma to attend the Cphi in Mumbai, India. December 3 - 5, 2013

Yes Pharma to attend the Cphi in Mumbai, India. December 3 - 5, 2013.  To schedule a meeting with our representative at the show click here >>

Read More

Yes Pharma to attend the Informex in Miami, USA. January 21 - 24, 2014

Yes Pharma to attend the Informex in Miami, USA - the global chemical marketplace event. January 21 - 24, 2014. To schedule a meeting with our representatives at the show, click here >>

Read More

New Press Release- April 12, 2013

YES Pharma Announces $2.5 Million Investment in Stereokem for 33% Ownership API Companies Synergize To Further Diversify Product Offerings and Increase Options for Customers (BEIT ...

Read More

Yes Pharma to attend the Informex- the global chemical marketplace event, Feb. 19-22, 2013

Yes Pharma will attend the Infomex event - the global chemical marketplace, on February 19-22, 2013 in Anaheim, California USA. To schedule a meeting with our reresentatives at the show, ...

Read More

November 2012: New Article - Regorafenib Approved to Treat Metastatic Colorectal Cancer

Main Bullet Points: On May 23, 2012 Bayer HealthCare announced their submission for approval of a potential blockbuster cancer drug- Regorafenib. On September 27, 2012 the FDA ...

Read More

August 2012: New Article: The Possibility of an Oral Insulin Treatment for Type 1 and Type 2 Diabetes is Near

Main Bullets: Patients who require insulin to keep their blood sugar levels under control need to meet a target HbA1c levels of less than 7% On July 11, 2012 Oramed, a developer ...

Read More

August 2012: New Article: Liraglutide Is an Efficacious Treatment for Type 2 Diabetes

Main Bullet points: * Liraglutide is a glucagon-like-peptide-1 (GLP-1) receptor agonist. * As a once daily injection, Liraglutide has proven to be effectual at lowering blood ...

Read More

August 2012: New article: Tofacitinib is a Viable Treatment for Ulcerative Colitis

* Currently in late-stage clinical trials for the treatment of ulcerative colitis, Tofacitinib was initially expected to gain FDA    approval on August 21, 2012 for its use ...

Read More

August 2012: New Article: Is Approval of Apixaban in the U.S. Near?

Main Bullet Points: *Apixaban praised at the 2012 International Stroke Conference. * The mortality rate of patients was higher for the group of participants who received aspirin as ...

Read More

August 2012: New Article: Pregabalin for Effectual, Quick and Tolerable Pain Relief

Main Bullet Points: * Pregabalin is effective for treating patients with fibromyalgia, diabetic nerve pain, and pain caused shingles.  * Pregabalin is equally as effectual for pain ...

Read More

August 2012 : New Article: Sitagliptin Phosphate Set to Soar in Sales

Main bullet points: On June 26, 2012 Evaluate Pharma revealed it's World Preview 2018 projections, which touted Sitagliptin Phosphate as a future blockbuster drug. Sitagliptin ...

Read More

August 2012 : New Article: Crizotinib is a unique treatment for non-small cell lung cancer

        Main Bullet points: The American Cancer Society indicates that the rate for men in the U.S. to develop Non- Small Cell Lung Cancer is one in ...

Read More

August 2012 : New Article - Life Extending Lenalidomide is a Viable Treatment Option

Main bullet points: Patients with myelodysplastic syndrome and multiple myeloma find treatment with Lenalidomide to be life extending. The patent for Lenalidomide, known as ...

Read More

Oct 2012: YES Pharma to Attend CPhI Tradeshow in Madrid, Spain

We will be attending the CPhl Tradeshow in Madrid, Spain, during October 9th - 11th, 2012. Please contact us at info@yespharma.com in order to book a meeting. We look forward to seeing you ...

Read More

 

Dun and Bradstreet